Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant radiotherapy plus toripalimab for resectable esophageal squamous cell carcinoma
ChiCTR2500112131Phase 2Completed
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shandong Cancer Hospital. Primary endpoint: Pathological complete response. Started Nov 2025; status: completed.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500112131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112131.